Pediatric-onset Behçet disease

Current Opinion in Rheumatology

Volumn 25, Issue 5, 2013, Pages 636-642

  Ozen, Seza ^a   Eroglu, Fehime K ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Beh et disease; child; genetics; GWAS; neuro Beh et; pathogenesis; vascular involvement

Indexed keywords

ALPHA INTERFERON; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; ETANERCEPT; GEVOKIZUMAB; GLUCOCORTICOID; GLYCOPROTEIN GP 130; HLA B27 ANTIGEN; HLA B51 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 8; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C; STAT4 PROTEIN; STEROID; TUMOR NECROSIS FACTOR;

ANEURYSM; ANTICOAGULATION; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE CLASSIFICATION; DISEASE COURSE; ENDOCARDITIS; EYE INFLAMMATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEART INFARCTION; HUMAN; IMMUNOLOGICAL PROCEDURES; INTRACARDIAC THROMBOSIS; META ANALYSIS (TOPIC); ONSET AGE; PATHOGENESIS; PERICARDITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA VASCULITIS; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULITIS; VEIN THROMBOSIS;

AGE OF ONSET; BEHCET SYNDROME; BIOLOGICAL PRODUCTS; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; VENOUS THROMBOSIS;

EID: 84881549656     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328363ea8b     Document Type: Review

References (34)

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013; 65:1-11.
2. Yazici H, Ugurlu S, Seyahi E. Behçet syndrome: is it one condition? Clin Rev Allergy Immunol 2012; 43:275-280.
3. Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010; 42:698-702.
4. Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010; 42:703-706.
5. Xavier JM, Shahram F, Davatchi F, et al. Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behçet's disease. Arthritis Rheum 2012; 64:2761-2772.
6. Lee YJ, Horie Y, Wallace GR, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. Ann Rheum Dis 2013. [Epub ahead of print]
7. Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B-51 and ERAP1. Nat Genet 2013; 45:202-207.
8. Hou S, Yang Z, Du L, et al. Identification of a susceptibility locus in STAT4 for Behçet's disease in Han Chinese in a genome-wide association study. Arthritis Rheum 2012; 64:4104-4113.
9. Masatlioglu S, Seyahi E, Tahir Turanli E, et al. A twin study in Behcet's syndrome. Clin Exp Rheumatol 2010; 28:S62-S66.
10. Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature 2008; 454:455-462.
11. Park H, Bourla AB, Kastner DL, et al. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 2012; 12:570-580.
12. Gul A, Ohno S. HLA-B-51 and Behcet disease. Ocul Immunol Inflamm 2012; 20:37-43.
13. DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009; 60:2633-2643.
14. Sawalha AH, Hughes T, Nadig A, et al. A putative functional variant within the UBAC2 gene is associated with increased risk of Behçet's disease. Arthritis Rheum 2011; 63:3607-3612.
15. Hou S, Shu Q, Jiang Z, et al. Replication study confirms the association between UBAC2 and Behcet's disease in two independent Chinese sets of patients and controls. Arthritis Res Ther 2012; 14:R70.
16. Hamzaoui K. Th17 cells in Behcet's disease: a new immunoregulatory axis. Clin Exp Rheumatol 2011; 29:S71-S76.
17. Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 2011; 128:655-664.
18. Liu X, Yang P, Wang C, et al. IFN-a blocks IL-17 production by peripheral blood mononuclear cells in Behcet's disease. Rheumatology 2010; 50:293-298.
19. Keino H, Watanabe T, Taki W, Okada AA. Effect of infliximab on gene expression profiling in Behcet's disease. Invest Ophthalmol Vis Sci 2011; 52:7681-7686.
20. Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum 2012; 64:2753-2760.
21. Tayer-Shifman OE, Seyahi E, Nowatzky J, Ben-Chetrit E. Major vessel thrombosis in Behcet's disease: the dilemma of anticoagulant therapy-the approach of rheumatologists from different countries. Clin Exp Rheumatol 2012; 30:735-740.
22. Krupa B, Cimaz R, Ozen S, et al. Pediatric Behcet's disease and thromboses. J Rheumatol 2011; 38:387-390.
23. Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Behcet disease: a series of 101 patients. Medicine (Baltimore) 2012; 91:18-24.
24. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine (Baltimore) 2012; 91:35-48.
25. Uluduz D, Kurtuncu M, Yapici Z, et al. Clinical characteristics of pediatriconset neuro-Behcet disease. Neurology 2011; 77:1900-1905.
26. Mora P, Menozzi C, Orsoni JG, et al. Neuro-Behcet's disease in childhood: a focus on the neuro-ophthalmological features. Orphanet J Rare Dis 2013; 8:18.
27. Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behcet's disease: a systematic review. J Neurol 2011; 258:719-727.
28. Ideguchi H, Suda A, Takeno M, et al. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore) 2011; 90:125-132.
29. Kone-Paut I, Darce-Bello M, Shahram F, et al. Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet's disease: an international cohort study of 110 patients: one-year follow-up data. Rheumatology 2010; 50:184-188.
30. Geri G, Wechsler B, Thi Huong du L, et al. Spectrum of cardiac lesions in Behcet disease: a series of 52 patients and review of the literature. Medicine (Baltimore) 2012; 91:25-34.
31. Saleh OA, Birnbaum AD, Tessler HH, Goldstein DA. Behcet uveitis in the American midwest. Ocul Immunol Inflamm 2012; 20:12-17.
32. Maldini C, LaValley MP, Cheminant M, et al. Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology 2012; 51:887-900.
33. Gul A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis 2011; 71:563-566.
34. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41:61-70.